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ost-effectiveness of a zotarolimus-eluting stent (ZES) compared with a paclitaxel-eluting stent (PES)
n patients with native coronary lesions.
ackground Early drug-eluting stents were associated with a small but signiﬁcant incidence of very
ate stent thrombosis (VLST), occurring 1 year after the index procedure. The ZES has shown en-
ouraging results in clinical trials.
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afety end points included Academic Research Consortium-deﬁned stent thrombosis. Economic end
oints analyzed included quality-adjusted survival, medical costs, and relative cost-effectiveness of ZES
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1209tudies with Food and Drug Administration-approved
rug-eluting stents (DES) with bio-stable polymers to
eliver potent antiproliferative agents (sirolimus, paclitaxel,
otarolimus, and everolimus) have demonstrated an im-
rovement in angiographic and clinical efficacy and compa-
able safety when compared with bare-metal stents (BMS)
n randomized clinical trials after 1-year follow-up (1–6).
See page 1236
owever, unlike BMS, early versions of DES (sirolimus-
luting stent [SES] and paclitaxel-eluting stent [PES]) were
ssociated with a disturbing complication, very late stent
hrombosis (VLST), which occurred after the first year of
ES implantation (7–9) and had previously only been
bserved after coronary vascular brachytherapy procedures
10,11). Although VLST after DES is a rare event, occur-
ing at a frequency varying from 0.2% to 0.6%/year (8), the
linical significance cannot be discounted, because almost all
atients suffer myocardial infarctions (MIs) or death. The
LST hazard might be constant for several years (12), and
here is an increased sensitivity to antiplatelet therapy
ithdrawal (13–15). Thus, clinical practice must be modu-
ated to account for possible VLST after DES, which has
esulted in more selective DES use and prolonged dual
ntiplatelet therapy considerations (16,17).
The design characteristics of the zotarolimus-eluting
tent (ZES) were intended to optimize patient safety.
xperimental results in animal models have indicated
hat ZES has improved healing responses and restored
ndothelial function compared with SES and PES, more
losely resembling a BMS (18 –20). Surrogate safety end
oints in patients, with intravascular ultrasound, angios-
opy, and optical coherence tomography, have also shown
eneficial ZES responses compared with earlier SES and
ES (21–24), and a pooled analysis with long-term
ollow-up of ZES-treated patients has indicated a fre-
uency of VLST 1%, which is similar to results after
MS treatment (25,26). Initial findings from the EN-
EAVOR IV trial (Randomized, Controlled Trial of the
edtronic Endeavor Drug [ABT-578] Eluting Coronary
tent System Versus the Taxus Paclitaxel-Eluting Cor-
emorial Hospital, Elyria, Ohio; #Lubbock Heart Hospital, Lubbock, Texas; **And
nd the ‡‡Emory University, Atlanta, Georgia. The ENDEAVOR IV clinical trial w
y Medtronic CardioVascular, Santa Rosa, California. Dr. Leon has served as a c
orporation. Dr. Kandzari has received research/grant support and consulting honora
r grant support from Medtronic, Inc. and Eli Lilly and Company. Dr. Anstrom has
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erved as Guest Editor for this article.anuscript received July 31, 2009; revised manuscript received October 13, 2009, acceptednary Stent System in De Novo Native Coronary Artery
esions) involving 1,548 patients with de novo native
oronary lesions have demonstrated similar clinical safety
nd efficacy of ZES compared with PES during the first
ear of follow-up (5). The purpose of this report is to
nalyze clinical safety, efficacy, and cost effectiveness with
xtended 2-year follow-up in the ENDEAVOR IV trial.
ethods
tudy design and patient population. The ENDEAVOR
V trial was a prospective, multicenter, single-blinded,
andomized, controlled clinical trial that compared clin-
cal and angiographic outcomes between patients treated
ith ZES and patients treated
ith PES. Consecutive adult
atients with clinical evidence
f ischemic coronary disease or
positive functional study were
nrolled at 80 centers in the
.S. The institutional review
oard at each site approved the
rotocol, and each eligible pa-
ient provided written, in-
ormed consent before the in-
ex procedure.
Description of the key inclu-
ion and exclusion criteria, study
evices, and procedural-related
etails has been previously re-
orted (5). After the interven-
ional procedure, patients were
valuated at 30 days, 6, 9, and 12
onths and yearly thereafter up
o 5 years after the procedure.
atients in the angiographic and
ntravascular ultrasound sub-
roups were assessed at 8
onths after the procedure.
ual antiplatelet therapy (aspi-
in and clopidogrel) was given for 6 months to all patients
er protocol and continued thereafter, at the discretion of
he managing physician.
edical Center, Anderson, South Carolina; ††Methodist Hospital, Houston, Texas;
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Abbreviations and
Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
DRG  diagnosis-related
group
MACE  major adverse
cardiac events
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
QALY  quality-adjusted
life year
ST  stent thrombosis
TLR  target lesion
revascularization
TVF  target vessel failure
VLST  very late stent
thrombosis
ZES  zotarolimus-eluting
stent(s)October 16, 2009.
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1210linical end points and deﬁnitions. The primary clinical end
oint in this clinical trial was target vessel failure (TVF),
efined as the composite of cardiac death, MI, or clinically
riven target vessel revascularization of the treated vessel at
months after the procedure. Pre-specified secondary
linical safety and efficacy end points included major adverse
ardiac events (MACE), defined as death, MI, or clinically
riven target lesion revascularization (TLR) (and individual
omponent end points) and stent thrombosis (ST) at annual
ollow-up. Myocardial infarction was defined as either: 1)
-wave MI requiring new pathologic Q waves in 2 or more
ontiguous electrocardiographic leads and either symptoms
onsistent with acute myocardial ischemia or elevation of
ardiac biomarkers; or 2) non–Q-wave MI requiring ele-
ated creatine kinase 2 the upper laboratory limit with
levated creatine kinase–myocardial band in the absence of
athological Q waves.
Stent thrombosis (both early and late) was adjudicated by
Table 1. Baseline Clinical and Angiographic Characteristics of the Study P
Patient demographics
Age (yrs)
Male
Diabetes
Hypertension
Hyperlipidemia
History of smoking
Prior MI
Prior percutaneous coronary intervention
Prior coronary bypass surgery
Angina
Stable
Unstable
MI
CCS class III or IV
Angiographic characteristics
Target vessel
Left anterior descending
Left circumﬂex
Right coronary
Type B2/C lesion
Number of diseased, native, major epicardial coronary vessels (50% stenosed)
Single
Double
Triple
Left ventricular ejection fraction (%)
Reference vessel diameter (mm)
Lesion length (mm)
Minimal lumen diameter (mm)
Diameter stenosis (%)
Values are % (n/total) or mean SD (n).
CCS Canadian Cardiovascular Society angina class; MImyocardial infarction; PES paclitaxesubcommittee of the clinical event committee, blinded to Gtudy stent identity and according to the definitions pro-
osed by the Academic Research Consortium (ARC) (27).
conomic end points and analyses. In addition to clinical
utcomes, an economic analysis was performed to deter-
ine the relative cost-effectiveness after treatment with
ES or PES. After identification of economic events with
ACE- and adverse event-related hospital stays, adverse
vent system organ class designations were used to distin-
uish cardiac from noncardiac hospital stays, and Medical
ictionary for Regulatory Activities preferred terms were
pplied to differentiate types of cardiac hospital stays. Each
tudy subject was assigned an index episode of care and a
ariable number of follow-up period episodes of care with a
ethod that combined economic event data. Outpatient
eaths were the only outpatient events.
Medical costs, length of stay, and quality of life estimates
ere assigned to episodes of care. The Centers for Medicare
nd Medicaid Services Medicare Severity Diagnosis Related
ion
ZES PES p Value
63.5 11.1 (773) 63.6 11.0 (775) 0.930
66.9% (517/773) 68.5% (531/775) 0.514
31.2% (241/773) 30.5% (236/775) 0.783
79.4% (614/773) 82.6% (640/775) 0.120
81.4% (629/773) 84.8% (657/775) 0.078
62.6% (479/765) 60.4% (462/765) 0.401
21.1% (161/764) 23.2% (176/759) 0.324
28.2% (218/773) 29.5% (229/775) 0.575
9.8% (76/773) 8.4% (65/775) 0.332
0.367
45.6% (281/616) 47.9% (292/609)
51.6% (318/616) 49.9% (304/609)
2.8% (17/616) 2.1% (13/609)
50.3% (309/614) 47.9% (292/610) 0.392
0.791
42.2% (326/772) 41.5% (321/774)
26.9% (208/772) 26.1% (202/774)
30.8% (238/772) 32.4% (251/774)
69.6% (537/772) 70.9% (549/774) 0.358
0.485
54.9% (424/772) 57.2% (443/774)
28.6% (221/772) 26.1% (202/774)
16.5% (127/772) 16.7% (129/774)
57.3 9.9 (760) 57.5 10.3 (753) 0.745
2.73 0.47 (772) 2.70 0.46 (774) 0.197
13.41 5.67 (771) 13.80 6.09 (773) 0.199
0.96 0.40 (772) 0.93 0.40 (774) 0.149
64.83 13.29 (772) 65.68 13.10 (774) 0.204
g stent(s); ZES zotarolimus-eluting stent(s).opulatrouper was used to associate diagnosis-related groups
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1211DRGs) to episodes of care (28), and these assignments
ere then audited by a trained medical record professional.
or cardiovascular episodes of care, medical costs and
engths of stay were estimated with Medicare national
verage payment amounts for 2008 (calculated with an
verage hospital Medicare base rate of $4,893) and arith-
etic mean lengths of stay by DRG (29,30). For noncar-
iovascular episodes of care, medical cost and length of stay
ere assigned with Medicare national average relative
eight and arithmetic mean length of stay. The DRG-
pecific costs for physician services were estimated with
ublished sources and adjusted to 2008 values with the
edical care component of the consumer price index (31). A
2,100 unit cost was assigned to both stent types (data on
Figure 1. Patient Disposition and Follow-Up
Patients were randomized (1:1) to a zotarolimus-eluting stent (ZES) or a
paclitaxel-eluting stent (PES). Patient follow-up (F/U) numbers for 1 and 2
years in each group are shown.
Table 2. Clinical Outcomes at 2 Years
Death (all)
Cardiac
Noncardiac death
MI (all)
Q-wave
Non–Q-wave
Death or MI
Cardiac death or MI
Target lesion revascularization
Target vessel revascularization
Nontarget lesion, target vessel revascularization
Target vessel failure
Major adverse cardiac events
Values are % (n).Abbreviations as in Table 1.le, Medtronic CardioVascular, Santa Rosa, California).
ecause the type of repeat percutaneous coronary interven-
ion procedure was not identified in the follow-up case
eport forms for this trial, results were extrapolated from the
epeat percutaneous coronary intervention procedures per-
ormed at a single participating center (Duke University
edical Center, Durham, North Carolina) during the
NDEAVOR IV study period. These data were used to
efine the distribution of different types of percutaneous
evascularization (32). Previously defined methods were
sed to assign quality of life weights (33), including a 0.79
uality-adjusted life year (QALY) adjustment for all revas-
ularization procedures, a 0.85 QALY adjustment for
oronary artery disease without revascularization, a 0.88
ermanent QALY adjustment when subjects experienced
nonfatal MI, and a quality adjusted life day decrement
or each day of estimated length of stay during a hospital
tay (34).
Number of hospital stays (revascularization, other car-
iac, noncardiac, and total), quality-adjusted survival (both
ndiscounted and discounted at 3%), and medical costs
both undiscounted and discounted at 3%) were computed
s 2-year cumulative values by treatment (ZES or PES) with
ifferences, 95% confidence intervals, and p values. Medical
osts also were presented by annual time periods. Analyses
ere performed with generalized linear models on parti-
ioned data with empirical standard errors and an adjust-
ent for censoring. We then performed a comprehensive
ost-effectiveness analysis to estimate the incremental med-
cal costs/QALY saved with the use of ZES versus PES
uring the 2-year follow-up period. This cost-effectiveness
atio was calculated with the nonparametric bootstrap pro-
edure, and results are shown as discounted mean values for
he ratio.
ZES
 742)
PES
(n  739) p Value
3.1 (23) 2.6 (19) 0.639
1.5 (11) 1.2 (9) 0.823
1.6 (12) 1.4 (10) 0.831
2.0 (15) 4.1 (30) 0.023
0.4 (3) 0.5 (4) 0.725
1.6 (12) 3.5 (26) 0.022
5.0 (37) 6.5 (48) 0.221
3.4 (25) 5.1 (38) 0.096
5.9 (44) 4.6 (34) 0.295
8.9 (66) 9.2 (68) 0.857
4.2 (31) 5.8 (43) 0.154
1.1 (82) 13.1 (97) 0.232
9.8 (73) 10.0 (74) 0.931(n
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1212tatistical methods. The randomized ENDEAVOR IV
rial was designed to compare the noninferiority primary
nd point (TVF at 9 months) between patients treated with
ES and those treated with PES (5). The primary objective
f this analysis was to compare clinical safety and effective-
ess outcomes between the 2 DES cohorts 2 years after the
ndex revascularization.
Categorical variables were compared by the chi-square or
isher exact test, as appropriate. Continuous variables are
escribed as means with SD and were compared by un-
aired t tests. Time-to-event data are reported and dis-
layed as Kaplan-Meier estimates, with comparisons be-
B
A
Figure 2. Cumulative Incidence of TVF and TLR at 2 Years
Hazard ratios (HR) with 95% conﬁdence intervals and cumulative incidence of
1 and 2 years are displayed. Abbreviations as in Figure 1.ween groups by the log-rank test. All analyses are by gntention-to-treat, with all patients randomized to each
tudy stent included.
All analyses were performed with SAS software (version
.2 or higher, SAS Institute, Cary, North Carolina). Data
ollection, clinical event adjudication, and analysis were
erformed at the Harvard Clinical Research Institute (Bos-
on, Massachusetts). All authors had full access to the
atabase and analysis upon which this manuscript is based.
esults
linical outcomes at 2 years. Baseline clinical and angio-
vessel failure (TVF) (A) and target lesion revascularization (TLR) (B) attargetraphic characteristics of the study population were similar
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1213mong ZES and PES patients (Table 1). Of the 1,548
atients enrolled in the ENDEAVOR IV trial, clinical
ollow-up was completed at 1 and 2 years in 97.5% and
6.0% of ZES patients and in 96.9% and 95.4% of PES
atients, respectively, (Fig. 1). The primary study end point,
VF, was 11.1% for ZES compared with 13.1% for PES
p 0.232) (Table 2, Fig. 2A). There were no differences in
eath, but there were significantly fewer non–Q-wave MIs
n ZES versus PES patients (1.6% vs. 3.5%; p  0.022,
able 2). There were no differences in overall clinically
riven TLR or target vessel revascularization events com-
aring ZES with PES at 2 years (Table 2, Fig. 2B). In those
atients with angiographic follow-up (18% of the total study
opulation), TLR at 2 years was 9.2% for ZES and 3.1% for
ES (p  0.045) (Fig. 3). In those patients without
ngiographic follow-up, TLR was 5.2% for ZES and 4.9%
or PES (p  0.896) (Fig. 3).
T WITHIN THE FIRST YEAR. Although there were no sig-
ificant differences in early or late ARC ST during the first
ear of follow-up among the treatment cohorts, there was a
rend toward more frequent ARC-definition (definite or
robable) ST with ZES compared with PES (0.9% vs.
.1%, p  0.07). Of the 7 ZES patients with ARC ST
definite or probable), 3 occurred before 30 days (2 definite
nd 1 probable) and 4 occurred between 30 days and 6
onths (3 definite and 1 probable). In the 3 ZES patients
ith ARC definite or probable ST before 30 days, 2 were
ssociated with edge dissections and incomplete stent ex-
ansion, and 1 had an unplanned surgical procedure. In the
ZES patients with ARC definite or probable ST between
0 days and 6 months, 3 patients were no longer taking dual
ntiplatelet therapy (time of dual antiplatelet therapy cessa-
ion to ST was 2 days, 20 days, and 2 months); 1 of which
Figure 3. TLR by Angiographic and Clinical Follow-Up to 2 Years
Number and percent TLR for patients with angiographic follow-up and clinicallso had an unplanned surgical procedure.ETWEEN 1 AND 2 YEARS. Academic Research Consortium
LST (definite or probable) occurred in 1 ZES patient and
n 6 PES patients (p  0.069) (Tables 3 and 4, Fig. 4). The
PES ST events were associated with no deaths and 3
-up at 2 years. Abbreviations as in Figure 1.
Table 3. Stent Thrombosis Through 2 Years
Outcome
ZES
(n  742)
PES
(n  739) p Value
Early (0–30 days)
Deﬁnite 0.3 (2) 0.1 (1) 1.000
Probable 0.1 (1) 0.0 (0) 1.000
Possible 0.0 (0) 0.0 (0) —
Deﬁnite/probable 0.4 (3) 0.1 (1) 0.624
Any 0.4 (3) 0.1 (1) 0.624
Late (31–360 days)
Deﬁnite 0.4 (3) 0.0 (0) 0.249
Probable 0.1 (1) 0.0 (0) 1.000
Possible 0.4 (3) 0.4 (3) 1.000
Deﬁnite/probable 0.5 (4) 0.0 (0) 0.124
Any 0.9 (7) 0.4 (3) 0.342
Very late (361–720 days)
Deﬁnite 0.1 (1) 0.7 (5) 0.124
Probable 0.0 (0) 0.1 (1) 0.499
Possible 0.4 (3) 0.3 (2) 1.000
Deﬁnite/probable 0.1 (1) 0.8 (6) 0.069
Any 0.5 (4) 1.1 (8) 0.264
Cumulative (0–720 days)
Deﬁnite 0.8 (6) 0.8 (6) 1.000
Probable 0.3 (2) 0.1 (1) 1.000
Possible 0.8 (6) 0.7 (5) 1.000
Deﬁnite/probable 1.1 (8) 0.9 (7) 1.000
Any 1.9 (14) 1.6 (12) 0.844
Values are % (n).Abbreviations as in Table 1.
Q
w
s
a
1
A
c
C
a
s
b
b
b
D
T
o
t
f
w
i
c
r
m
s
a
Z
m
l
a
d
g
d
E
P
y
T
2
(
apy; DE
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 2 , 2 0 0 9
D E C E M B E R 2 0 0 9 : 1 2 0 8 – 1 8
Leon et al.
2-Year Follow-Up From the ENDEAVOR IV Trial
1214-wave and 3 non–Q-wave MIs, and 3 of the 6 patients
ere no longer receiving clopidogrel therapy (Table 4). The
ole ZES VLST case was associated with a Q-wave MI in
patient who stopped taking both aspirin and clopidogrel
0 days before the ST event. The cumulative incidence of
RC definite or probable ST after 1 year mirrored the
umulative incidence of MIs after 1 year (Fig. 5).
ost-effectiveness. There were no differences in quality-
djusted survival or medical costs (initially, during the
econd year, or cumulative during the 2 years of follow-up)
etween ZES and PES patient cohorts (Table 5). Similarly,
ootstrap analysis of the 2-year cost-effectiveness showed no
enefit of ZES compared with PES patients (Fig. 6).
iscussion
he key findings of the present analysis assessing clinical
utcomes after 2 years in patients treated with ZES versus
hose treated with PES for single de novo coronary lesions
rom the randomized ENDEAVOR IV trial (1,548 patients
ith 95% follow-up) are: 1) up to 2 years after stent
Figure 4. ARC-Defined Stent Thrombosis at 1 to 2 Years
Table 4. ARC Definite/Probable Stent Thrombosis Up
DES ARC Definition
Time to Eve
(Days)
PES Deﬁnite 413
Deﬁnite 495
Deﬁnite 619
Deﬁnite 645
Deﬁnite 689
Probable 697
ZES Deﬁnite 369
ARC Academic Research Consortium; DAPT dual antiplatelet therAcademic Research Consortium (ARC)-deﬁned stent thrombosis rates for the secondmplantation, the ZES— compared with the PES—
ontinued to demonstrate comparable clinical anti-
estenosis efficacy; 2) ZES seemed to have a more favorable
id-term safety profile, with fewer episodes of VLST and
ignificantly less MI in patients compared with PES; and 3)
t 2 years, there was similar cost-effectiveness comparing
ES and PES.
Very late stent thrombosis and in-stent restenosis, the
ain 2 concerns after DES implantation, require meticu-
ous long-term clinical follow-up to ensure patient safety
nd to determine whether overall clinical effectiveness is
urable (7–9). Despite significantly higher 8-month angio-
raphic in-stent late loss in ZES-treated patients, ischemia-
riven TLR between 1 and 2 years were infrequent in the
NDEAVOR IV trial and similar for both ZES (1.6%) and
ES (1.7%), and cumulative ischemia-driven TLR at 2
ears was likewise similar for ZES (5.9%) and PES (4.6%).
he clinical efficacy results for the ENDEAVOR IV trial at
years are consistent with multiple other ZES studies
35–39), suggesting the absence of a “late catch-up” phe-
Years
Clinical Event DAPT at Event
Q-wave MI ASA only
Non–Q-wave MI ASA  clopidogrel
Non–Q-wave MI ASA  clopidogrel
Q-wave MI ASA only
Non–Q-wave MI ASA only
Q-wave MI ASA  clopidogrel
Q-wave MI None
S drug-eluting stent(s); other abbreviations as in Table 1.to 2
ntyear after stent implantation. Abbreviations as in Figure 1.
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1215omenon and a durable effect on the reduction of clinical
estenosis over time (26,38,40–42). Because recent reports
ave indicated concerns associated with increasing late loss
nd related late TLR events after 1 year with other DES
43,44), these ZES findings bear watching as further clinical
ollow-up is accumulated in the ENDEAVOR IV trial and
ther ZES clinical trials involving more complex lesion
ubsets (39,45). It is interesting to note that the 2-year
esults from the ENDEAVOR IV trial continue to empha-
ize the significant impact of angiographic follow-up on
ubsequent TLR events. In the subset of patients with
lanned angiographic follow-up, there were significant dif-
erences in 2-year TLR rates (ZES 9.2% vs. PES 3.1%, p
.045), whereas in those patients without angiographic
ollow-up (82% of the study population), there were no
ifferences in 2-year TLR (ZES 5.2% vs. PES 4.9%, p 
.896).
Because stent-related coronary thrombosis during the
rst year after implantation is known to be associated with
Figure 5. Landmark Analysis of Incidence of Myocardial Infarction During t
and PES Implantation
The HRs with 95% conﬁdence intervals for 0 to 1 year and 1 to 2 years are sho
and 2.
Table 5. 2-Year QA Survival and Medical Costs
Taxus
Survival (days) 711.22
Discount survival (days)* 690.09
Quality-adjusted survival (days) 575.41
Discount QA survival (days)* 557.97
Medical costs ($)
Initial year 17,713
Second year 2,316
Cumulative 2-yr costs 20,029
Cumulative discount 2-yr costs* 19,852
*Discount rate of 3%/year.CI confidence interval; QA quality-adjusted.ultiple patient, lesion, and procedural predictors
25,46,47) that vary from study to study, we have empha-
ized the importance of very late (after 1 year) thrombosis
vents, which seem to be related to fundamental design
haracteristics of DES. The 2-year clinical outcomes from
he ENDEAVOR IV trial reinforce the impression that
ES are similar to BMS from the standpoint of late safety,
ncluding VLST. However, it bears noting that the EN-
EAVOR IV trial was not powered to demonstrate differ-
nces in safety end points such as cardiac death plus MI or
T, and after 2-year follow-up, the only statistically signif-
cant benefit of ZES over PES was a reduction in non–Q-
ave MIs (3.5% vs. 1.6%, p  0.022). Moreover, there are
ata from other recent randomized trials similarly under-
owered to discern differences in ST, which compare ZES
ith other DES (both SES and PES) during the first year
f follow-up. These studies show no consistent differences
n ST during the first year of clinical follow-up (48,49). The
argest randomized trial (8,800 patients, with enrollment
st Year and Between the First and Second Years After ZES
r the incidence rates of myocardial infarction. Abbreviations as in Figures 1
ndeavor Difference (95% CI) p Value
711.00 0.21 (6.07 to 6.49) 0.95
689.89 0.20 (5.85 to 6.24) 0.95
576.00 0.60 (5.95 to 4.75) 0.83
558.56 0.59 (5.74 to 4.56) 0.82
7,167 545 (178 to 1,269) 0.14
2,454 137 (782 to 510) 0.68
9,621 408 (632 to 1,269) 0.44
9,440 411 (600 to 1,423) 0.43he Fir
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1216ompleted) focusing on the comparative safety of ZES
ersus SES was designed to provide a more definitive answer
o long-term (3-year) safety in a real-world patient popula-
ion (45).
In the ENDEAVOR IV trial, there were more MIs in
he PES group after 1 year due to a higher incidence of
LST events (1 event with ZES vs. 6 with PES). The 1
ES patient with VLST had stopped taking both ASA and
lopidogrel 10 days before the thrombosis event. These
ndings are similar to previous ZES studies versus BMS or
ES (37,40,41). Moreover, a pooled analysis of all adjudi-
ated ZES clinical trials with long-term follow-up indicated
VLST frequency of only 0.2% in over 2,000 ZES patients
26,42). Combined with higher rates of periprocedural MIs
n PES patients, possibly related to increased side branch
cclusions associated with PES stents (5,50), the overall
arly and late safety profile of ZES in the ENDEAVOR IV
rial was favorable compared with PES.
The comprehensive cost-effectiveness analysis that was
mbedded in the ENDEAVOR IV study design indicated
o differences in quality-adjusted survival, medical costs,
nd cost-effectiveness, either acutely or at 2 years, compar-
ng ZES versus PES treatment.
tudy limitations. The patients and lesions treated in the
NDEAVOR IV study were not highly complex, and
herefore, the results of this study cannot be extrapolated to
atients with more complex coronary anatomy. This study
as not designed or powered to compare rates of infrequent
Figure 6. Bootstrap Results for the 2-Year Cost-Effectiveness
Results are shown as discounted mean values for the cost-effectiveness ratio.dverse clinical events such as death, MI, or ST; therefore, Lhe results and trends should be interpreted as largely
ypothesis-generating. Finally, longer follow-up is neces-
ary to adequately assess late safety and efficacy events when
omparing ZES and PES therapies.
onclusions
his analysis of the ENDEAVOR IV trial demonstrates
hat the initial comparable clinical efficacy of ZES
ompared with PES is sustained at 2 years, with a
imilarly low rate of TLR and no differences in either
VF or MACE. Comparable clinical outcomes resulted
n similar 2-year cost-effectiveness. These findings, cou-
led with the low incidence of VLST and lower incidence
f MI after ZES versus PES implantation, provide
vidence supporting the mid-term safety and efficacy of
ES in the treatment of de novo lesions in native
oronary arteries. Longer follow-up of the ENDEAVOR
V trial and confirmation from additional randomized
rials are necessary to substantiate these findings.
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